Patents by Inventor Barry L. Stoddard
Barry L. Stoddard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240091346Abstract: Anti-Epstein Barr Virus (EBV) vaccines are described herein. The EBV vaccine antigens are linked to a multimerization domain, for example, presented on a circular tandem repeat protein (cTRP) scaffold or linked to a C4b multimerization domain. The vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.Type: ApplicationFiled: August 29, 2023Publication date: March 21, 2024Applicant: Fred Hutchinson Cancer CenterInventors: Jason Price, James M. Olson, Andrew McGuire, Barry L. Stoddard
-
Patent number: 11879018Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.Type: GrantFiled: June 28, 2021Date of Patent: January 23, 2024Assignee: Fred Hutchinson Cancer CenterInventors: Philip Bradley, Barry L. Stoddard
-
Publication number: 20230398208Abstract: SARS-CoV-2 vaccines are described herein. The SARS-CoV-2 vaccine antigens can be presented on a circular tandem repeat protein (cTRP) scaffold as trimers or tetramers. The vaccines can be used to treat and/or reduce the risk of SARS-CoV-2 infection and to treat and/or reduce the risk of side effects associated with SARS-CoV-2 infection, such as SARS-CoV-2-related symptoms, syndromes, and complications.Type: ApplicationFiled: June 8, 2023Publication date: December 14, 2023Applicant: FRED HUTCHINSON CANCER CENTERInventors: Jason Price, James Olson, Colin E. Correnti, Barry L. Stoddard
-
Publication number: 20220411472Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.Type: ApplicationFiled: July 2, 2020Publication date: December 29, 2022Applicant: Fred Hutchinson Cancer CenterInventors: Barry L. Stoddard, Philip Bradley, Colin E. Correnti
-
Publication number: 20220135627Abstract: Provided herein are novel thermostable phycobiliproteins. These proteins may be stabilized by the introduction of disulfide bonds which stabilize the protein. Modified cells expressing these thermostable phycobiliproteins and methods of making them are also provided.Type: ApplicationFiled: July 16, 2019Publication date: May 5, 2022Inventors: James ROBERTS, Ryo TAKEUCHI, Nhi KHUONG, Barry L. STODDARD, Rolf KUESTNER
-
Publication number: 20210388119Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.Type: ApplicationFiled: June 28, 2021Publication date: December 16, 2021Applicant: Fred Hutchinson Cancer Research CenterInventors: Philip Bradley, Barry L. Stoddard
-
Patent number: 11078300Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.Type: GrantFiled: February 26, 2020Date of Patent: August 3, 2021Assignee: Fred Hutchinson Cancer Research CenterInventors: Philip Bradley, Barry L. Stoddard
-
Publication number: 20200190220Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.Type: ApplicationFiled: February 26, 2020Publication date: June 18, 2020Applicant: Fred Hutchinson Cancer Research CenterInventors: Philip Bradley, Barry L. Stoddard
-
Patent number: 10619140Abstract: Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) and/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human ?-globin locus; (d) to disrupt a HbF silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbF silencing region; (e) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; (f) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; and/or (g) to correct one or more ?-globin gene mutation(s).Type: GrantFiled: March 16, 2017Date of Patent: April 14, 2020Assignee: Fred Hutchinson Cancer Research CenterInventors: Ryo Takeuchi, Mark T Groudine, Barry L. Stoddard, Michael A Bender
-
Patent number: 10597466Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.Type: GrantFiled: December 2, 2016Date of Patent: March 24, 2020Assignee: FRED HUTCHINSON CANCER RESEARCH CENTERInventors: Philip Bradley, Barry L. Stoddard
-
Publication number: 20190002590Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.Type: ApplicationFiled: December 2, 2016Publication date: January 3, 2019Applicant: Fred Hutchinson Cancer Research CenterInventors: Philip Bradley, Barry L. Stoddard
-
Publication number: 20170298329Abstract: Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) and/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human ?-globin locus; (d) to disrupt a HbF silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbF silencing region; (e) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; (f) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; and/or (g) to correct one or more ?-globin gene mutation(s).Type: ApplicationFiled: March 16, 2017Publication date: October 19, 2017Inventors: Ryo Takeuchi, Mark T Groudine, Barry L. Stoddard, Michael A Bender
-
Publication number: 20150166969Abstract: Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) ad/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human ?-globin locus; (d) to disrupt a HbP silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbP silencing region; (e) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; (f) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; and/or (g) to correct one or more ?-globin gene mutation(s).Type: ApplicationFiled: February 22, 2013Publication date: June 18, 2015Applicant: Fred Hutchinson Cancer Research CenterInventors: Ryo Takeuchi, Mark T Groudine, Barry L. Stoddard, Michael A Bender
-
Publication number: 20140148361Abstract: The present disclosure provides compositions and methods for producing and expressing variant or engineered I-OnuI endonucleases, variant or engineered I-OnuI homologues, and hybrids of two I-OnuI or I-OnuI homologue domains that have a target site altered from the wild-type. A method for selecting a variant or engineered I-OnuI endonuclease, I-OnuI endonuclease homologue, and a hybrid of two I-OnuI or I-OnuI homologue domains that have a target site altered from the wild-type and directed to a site within a gene of interest is also provided.Type: ApplicationFiled: June 7, 2011Publication date: May 29, 2014Inventors: Barry L. Stoddard, Abigail Rose Lambert, Ryo Takeuchi, Andrew M. Scharenberg, Sarah Katherine Baxter
-
Publication number: 20110294217Abstract: An engineered highly specific DNA-cleavage enzyme delivers a site-specific nick in a double stranded DNA, to cleave one DNA strand within its target site while leaving the opposing DNA strand intact. The engineered enzyme provides the ability to induce a gene conversion event in a mammalian cell. An engineered sequence-specific nickase derived from a LAGLIDADG homing endonuclease is altered by a single amino acid residue, wherein the amino acid residue is involved in the polarization of solvent molecules and acid-base catalysis in the active site without affecting direct contacts between the enzyme and either the bound DNA or bound metal ions. Engineered, site-specific nickase variants, such as of I-AniI and other homing endonucleases, are particularly useful in targeted genome engineering as well as therapeutic, targeted gene repair.Type: ApplicationFiled: February 12, 2010Publication date: December 1, 2011Applicant: FRED HUTCHINSON CANCER RESEARCH CENTERInventors: Audrey McConnell-Smith, Barry L. Stoddard